__

NEWS

Aurealis Therapeutics doses first DFU patient in Phase 1/2A clinical trial

11 February 2020

Aurealis Therapeutics AG, Basel, announced today that the first patient enrolled in its Phase 1/2A clinical trial for diabetic foot ulcer (DFU) has been dosed with AUP-16. AUP-16 is the first scalable, genetically engineered bacterial cell therapy that produces and secretes three human therapeutic proteins in the target tissue at unparalled low cost-of-goods. See press announcement here

Inanna AG added to the portfolio of OSICOS companies

December 2019

OSICOS is proud to announce that Inanna AG, a Zurich based start-up company committed to improve the outcomes of IVF treatments through machine learning, has become a portfolio company of OSICOS. We welcome Amra Wägli and her team and look forward to a succesful journey with Innana. For more details on Inanna please see the website here.

OSICOS AG moves into new offices downtown Zurich

1 February 2020

We are pleased to announce that we have moved into brand new offices at Schifflände 26 downtown Zurich. The new offices will allow us to grow to cope with the growth of number and demands of our portfolio companies. As from 1 February 2020 you find us here.

Cellestia raises CHF 20 million in Series B Financing

17 December 2019

Cellestia Biotech AG, Basel, announced today the closing of its Series B financing round raising a total of CHF 20 million and strengthens its Board with Guido Guidi as new Chairman and Robert Karsunky as new Chair of the Audit Committee. See press announcement here

CUTISS wins Swiss Technology Award 2019

21 November 2019

CUTISS AG, Zurich, has been awarded with the Swiss Technology Award 2019 as best Start-up company. Congratulations to the entire team! See press announcement here

Aurealis Therapeutics receive Clinical Trial Approval for first human clinical trial

27 September 2019

Aurealis Therapeutics AG, Basel, announced today that it received Clinical Trial Approval for its AUP-16 phase 1 diabetic foot ulcer (DFU) patient trial by the German Health Authority Paul-Ehrlich-Institute. AUP-16 is Aurealis Therapeutics' first product candidate using its proprietary "three-in-one" technology entering human clinical trials. See press announcement here

OSICOS companies at TOP100 Start-up Award - congratulations to the fantastic results

4 September 2019

The following of the start-up companies OSICOS has the honor and pleasure to advice achieved fantastic results in the TOP100 Start-up Award 2019:

CUTISS AG defends its #1 biotech position from last year on overall 6th rank

CELESSTIA Biotech AG moving up to 19th position

AgroSustain SA enters the ranking as #46 and best newcomer

Elthera AG remaining under the TOP100 ranking at #77

See all TOP100 results here.

Strekin completes recruitment in phase III RESTORE trial

12 September 2019

Strekin AG, Basel, announced today that the recruitment for its phase III clinical trial with its lead compound STR001 in Sudden Sensorineural Hearing Loss (RESTORE trial) has been completed and that top-line data from this trial are expected early 2020. See press announcement here

Strekin closes Series A Financing Round

3 September 2019

Strekin AG, Basel, has closed its Series A financing round to secure completion of its ongoing phase III RESTORE clinical trial and preparation of the NDA filing in Europe after trial results will be available early 2020. See press announcement here

Great Coverage of several OSICOS companies at CNN 

August 2019

Several of the start-up companies OSICOS has the honor and pleasure to advice have been covered by CNN Switzerland.

For UMAMI see here

For Cutiss see here

For AgroSustain see here

CUTISS wins Innosuisse grant to support automation project with CSEM

19 August 2019

CUTISS AG, Zurich, and CSEM have partnered in the denovoCast project to develop the first-ever automated machine to bioengineer personalised skin grafts for therapy and have been awarded a grant of more than CHF 0,8 mio by Innosuisse to support the project. See press announcement here

Aurealis Pharma submits its clinical trial application for first-in-human clinical study

15 October 2018

Aurealis Pharma AG, Basel, announced today that it submitted a clinical trial application (CTA) for its First-in-Human Phase 1-2A Clinical Study to the German Health Authority Paul-Ehrlich Institute (PEI) for its lead compound AUP1602-C in diabetic foot ulcers (DFU). Read full press release here.

Three OSICOS companies in TOP 100 Start-Up Ranking: Cutiss, Cellestia and Elthera

5 September 2018

At this year's Swiss Start-up TOP 100 Award, Cutiss was ranked #5, Cellestia Biotech as #48 and newcomer Elthera as # 55. Congratulations - proud to be part of these fantastic companies! See full ranking here.

Cellestia Biotech closes Series A Financing with CHF 20 million

19 December 2018

Cellestia Biotech announced today that it has closed its Series A Financing Round with a total of CHF 20 million from FC Capital, PPF / Sotio, ETP Ventures as well as existing and new private investors. The proceeds of this Series A will allow Cellestia to complete the ongoing Phase I clinical trial of its lead compound CB-103 and to advance the R&D pipeline. Read more

Celletsia Biotech AG gets green light to move ahead with its IND

4 February 2019

Cellestia received the green light from the FDA for its Investigational New Drug Application (IND). The FDA completed its review, and concluded that Cellestia can proceed with its clinical investigation of CB-103 in tumors driven by an oncogenic NOTCH signaling pathway.

Aurealis Pharma AG closes a CHF 7,8 mio financing round and separates its lead program in a new Basel-based entity named Aurealis Therapeutics AG

8 February 2019

Aurealis Pharma AG, Basel, announced today that it has closed a CHF 7,8 mio financing round with private and institutional investors. Also, Aurealis Pharma completed the de-merger of its lead program AUP-16 about to start human clinical trials into a seperate entity named Aurealis Therapeutics AG in Basel. Read full press release here.

CUTISS receives SME Instrument funds

31 July 2018

CUTISS AG, Zurich, developing denovoSkin, has received a € 2,5 mio grant under the EU SME Instrument funds as one of only three Swiss companies. This adds another substantial amount of financing on top of the Series A closed in June 2018 (see below) and gives Cutiss the required resources to move quickly forward in the developmet of it's lead product and automation program for GMP manufacturing. See press announcement here

CUTISS closes Series A Financing Round raising CHF 7,255 mio and strengthens its Board by electing Giammaria Giluiani as additional Board member 

25 June 2018

CUTISS AG, Zurich, announced the sucessful closing of its Series A Financing Round - see full press release here

At its first annual shareholder meeting on 25 June 2018, all proposals made by the Board were approved by the shareholders, inclusive the re-election of the current Board members Prof. Martin Meuli, Dr. Daniela Marino, Dr. Anja König and Prof. Ernst Reichmann and the election of Giammaria Giuliani as additional Board member.

Aurealis Pharma to add Iain Buchanan to its Board 

22 May 2018

Aurealis Pharma AG, Basel, announced today that the shaerholders meeting had elected Iain Buchanan as additional member to the Board of directors. Read full press release here.

Cutiss' CEO Daniela Marino and Elthera's CEO Anne Schmidt selected as members of the Swiss National Startup Team Life-Sciences 2018

5 April 2018

Ten new startups including Cutiss and Elthera have been selected by venturelab to become the next Venture Leaders Life Sciences 2018, chosen from among the most promising Life Sciences startups in Switzerland. As members of this prestigious team, Daniela and Anne will be on roadshow in Boston 27th May through 3rd June. OSICOS wishes them and the other eight life-sciences start-ups a successful week in Boston.  See full press release here.

Cutiss' CEO Daniela Marino and Elthera's CEO Anne Schmidt selected as members of the Swiss National Startup Team Life-Sciences 2018

5 April 2018

Ten new startups including Cutiss and Elthera have been selected by venturelab to become the next Venture Leaders Life Sciences 2018, chosen from among the most promising Life Sciences startups in Switzerland. As members of this prestigious team, Daniela and Anne will be on roadshow in Boston 27th May through 3rd June. OSICOS wishes them and the other eight life-sciences start-ups a successful week in Boston.  See full press release here.

Cellestia Biotech initiates phase I - IIA clinical study

4 January 2018

Cellestia Biotech AG, Basel, announced the initiatin of its first-in-human phase I–IIa clinical study with its lead development candidate CB-103 in Switzerland. See full press release here.

Elthera announces positive preclinical Proof of Concept (POC) Studies and Start of New Financing

March 2018

Elthera AG, Zug, announced to have achieved positive proof of concept data in preclinical studies and initiates new financing round. See full press release here.

CUTISS Ph II Clinical Study approved by Swissmedic 

February 2018

CUTISS AG, Zurich, receives Swissmedic approval to commence phase II denovoSkin™ trial for reconstructive surgery in adults and children. See full press release here

CUTISS granted CTI label 

7 November 2017

CUTISS AG, Zurich, developing denovoSkin, has been awarded with the prestigious CTI Start up Label from the Swiss Federal Commission for Technology and Innovation. See full press release here

CUTISS ready to start phase IIB clinical trials 

2 November 2017

CUTISS AG, Zurich, developing denovoSkin, has received approval from Swissmedic to start its phase IIB clinical trial in Switzerland. See full press release here

Cellestia Biotech receives Swissmedic aproval for the phase I - IIA clinical study

3 October 2017

On October 3rd Cellestia Biotech AG, Basel, received approval for its first-in-human phase I–IIa clinical study with its lead development candidate CB-103 in Switzerland.

CUTISS raises CHF 1 million in Seed Financing 

1 September 2017

CUTISS AG, Zurich, developing denovoSkin, a personalized, bio-engineered, dermo-epidermal skin graft, has raised CHF 1 million seed finnacing. See full press release here

Cellestia Biotech enters clinical development for its lead compound CB-103

14 August 2017

Cellestia enters clinical development for its lead compound CB-103, a new mode of action anticancer drug targeting NOTCH positive cancers following receipt of approval of its first-in-human Phase I – IIa clinical study. Read more

Aurealis Pharma closes CHF 5.6 million Series A Financing 

August 25, 2017

Aurealis Pharma announced today the closing of a CHF 5,6 milion Series A funding provided by Swiss and foreign private investors, Finvera plc and Tekes, the Finish Funding Agency for Innovation. Read more

Aurealis Pharma closes CHF 5.6 million Series A Financing 

25 August 2017

Aurealis Pharma announced today the closing of a CHF 5,6 milion Series A funding provided by Swiss and foreign private investors, Finvera plc and Tekes, the Finish Funding Agency for Innovation. Read more

Strekin raises CHF 10 million in seed financing

31 May 2017

Strekin AG secures CHF 10 million financing for further development of STR001 in Sudden Hearing Loss.

Read more

Cellestia Biotech raises CHF 8 million

26 January 2017

Cellestia Biotech raises CHF 8 million seed financing from private investors and PPF Group to advance its lead anti-cancer compound CB-103 to clinical development stage. Read more

AgroSustain seals cooperation with Migros and wins startup pitch competition

18 February 2020

AgroSustain SA, Nyon, announced that it sealed a cooperation with Switzerland's leading retailer Migros-Genossenschafts-Bund for a healthy and eco-friendly way to keep fruits and vegetables fresh and durable. See press announcement: here

Further, AgroSustain SA, Nyon, won the startup pitch competition of the Swiss-Colombian Academia-Industry Camp which is endowed with CHF 10'000. See press announcement: here  

Congratulations to the entire team to these achievements!

Schifflände 26, 8001 Zurich, Switzerland

+41 (0) 44 923 11 88  

©2020 BY OSICOS LTD